Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.

Annals of internal medicine - 2 Sept 2003

Squires Kathleen, Pozniak Anton L, Pierone Gerald, Steinhart Corklin R, Berger Daniel, Bellos Nicholaos C, Becker Stephen L, Wulfsohn Michael, Miller Michael D, Toole John J, Coakley Dion F, Cheng Andrew

Abstract excerpt

BACKGROUND: Resistance to antiretroviral agents remains a leading cause of treatment failure for patients infected with HIV-1. OBJECTIVE: To describe the efficacy and safety of tenofovir disoproxil fumarate (tenofovir DF) compared with placebo in patients with detectable viral replication despite...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Anti-HIV Agents
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Organophosphonates

Share to Organophosphorus Compounds

Share to Placebos

Share to Tenofovir

Source

Identifiers

PMID: 12965939
DOI: 10.7326/0003-4819-139-5_part_1-200309020-00006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-12965939-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.PMID 12965939Read ↗

Tenofovir disoproxil fumarate.Semantic proximity Read ↗

Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.Semantic proximity Read ↗

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.Semantic proximity Read ↗

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.Semantic proximity Read ↗

Tenofovir disoproxil fumarate.Semantic proximity Read ↗

Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.Semantic proximity Read ↗

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.Semantic proximity Read ↗

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.Semantic proximity Read ↗

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.Semantic proximity Read ↗

Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.Semantic proximity Read ↗

In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.Semantic proximity Read ↗

Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.